CHONGQING PHARSCIN PHARMACEUTICAL CO., LTD.

Chongqing Pharscin Pharmaceutical Co., Ltd.

002907

CNE100003308

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
13.31 ^CNY	-0.30%		+3.98%	-13.85%

Apr. 10	Chongqing Pharscin Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023	CI
Apr. 03	Pharscin Pharma Gets License to Produce Olmesartan Medoxomil Amlodipine Tablets	MT

Chengdu Shangyi Information Technology Co., Ltd. announced that it has received $15.45 million in funding from Deyi Capital, Chongqing Pharscin Pharmaceutical Co., Ltd.

August 26, 2021

Chengdu Shangyi Information Technology Co., Ltd. announced that it has received $15,450,000 in a round of funding from Deyi Capital, Chongqing Pharscin Pharmaceutical Co., Ltd. on August 27, 2021.

Latest news about Chongqing Pharscin Pharmaceutical Co., Ltd.

Chongqing Pharscin Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023	Apr. 09	CI
Pharscin Pharma Gets License to Produce Olmesartan Medoxomil Amlodipine Tablets	Apr. 03	MT
Pharscin Pharmaceutical Amends Colon Cleanser Drug's Validity Period	Jan. 24	MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Pharscin Pharmaceutical Gets FDA Nod on Buspirone Hydrochloride Tablets	23-10-12	MT
Chongqing Pharscin Pharmaceutical Co., Ltd.(XSEC:002907) added to S&P Global BMI Index	23-09-18	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-20	CI
Pharscin Pharmaceutical Gets Nod to Amend Usage of Bawei Qilong Granules	23-08-18	MT
Pharscin Pharma's Production Base Passes US FDA Inspection	23-07-12	MT
Pharscin Pharma Gets Approval for Supplementary Application of Traditional Chinese Medicine	23-06-12	MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Implements Final Cash Dividend of A shares for 2022, Payable on June 13, 2023	23-06-05	CI
Chongqing Pharscin Pharmaceutical Co., Ltd Approves the Cash Dividend for 2022	23-05-22	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Pharscin Pharma Obtains China Marketing Rights to Hypertension Drug; Shares Drop 4%	23-02-20	MT
Pharscin Pharma’s Profit Rises 3.5% in 2022 Despite 7% Drop in Revenue	23-02-13	MT
Chengxin Rating Terminates Pharscin Pharma’s Credit Ratings After Bond Redemption	23-01-04	MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-16	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Announces Final Profit Distribution on A Shares for the Year 2021, Payable on July 14, 2022	22-07-06	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Approves 2021 Profit Distribution Plan	22-05-19	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Announces Board Changes	22-05-19	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Announces Final Dividend Proposal for 2021	22-04-20	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-25	CI
Chengdu Shangyi Information Technology Co., Ltd. announced that it has received $15.45 million in funding from Deyi Capital, Chongqing Pharscin Pharmaceutical Co., Ltd.	21-08-26	CI

Chart Chongqing Pharscin Pharmaceutical Co., Ltd.

Duration

Period

Chart Chongqing Pharscin Pharmaceutical Co., Ltd.

More charts

Chongqing Pharscin Pharmaceutical Co Ltd is a China-based company principally engaged in the research, development, production and sale of Chinese patent drugs and chemical drugs. The Company operates three segments: Pharmaceutical Industry segment, Commercial Circulation segment and Retail segment. The Company's products are categorized into the pharmaceuticals of digestive system, nervous system, otorhinolaryngology, cardiovascular and cerebrovascular systems and immune systems. The Companyâs products include Weidimei (aluminum carbonate tablets), Ganju Bingmei Tablets, Bawei Qilong Particles, Liuwei Anshen Capsules, Sodium Ferulate for Injection, Omeprazole Sodium for Injection and Gabexate Mesilate for Injection. The Company mainly distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

2024-04-28 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
CHONGQING PHARSCIN PHARMACEUTICAL CO., LTD.	-13.85%	767M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B